Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer (Q33331583)

25 July 2017

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer (English)

1 reference

25 July 2017

1 reference

K D Miller

1

1 reference

25 July 2017

J Picus

2

1 reference

25 July 2017

C Blanke

3

1 reference

25 July 2017

W John

4

1 reference

25 July 2017

J Clark

5

1 reference

25 July 2017

L N Shulman

6

1 reference

25 July 2017

D Thornton

7

1 reference

25 July 2017

E Rowinsky

8

1 reference

25 July 2017

P J Loehrer

9

1 reference

25 July 2017

1 January 2000

1 reference

25 July 2017

1 reference

25 July 2017

11

1 reference

25 July 2017

1

1 reference

25 July 2017

101-103

1 reference

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

25 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Clinical studies with MTA.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Identifiers

DOI

10.1023/A:1008305205159

1 reference

25 July 2017

1 reference